PDF(Pubmed)
Abstract：
To evaluate respiratory outcomes in preterm infants with retinopathy of prematurity (ROP) following intravitreal bevacizumab injection (IVB).
This single-centre study enroled preterm infants with a gestational age (GA) < 34 weeks or a birth weight (BW) < 1500 g with bilateral type 1 ROP who received a single IVB, and a treatment-free control group matched by GA, postmenstrual age, and respiratory status at the time of the IVB. The primary outcome was serial respiratory changes in mean airway pressure (MAP), fraction of inspired oxygen (FiO2), and respiratory severity score (RSS, MAP x FiO2) during the 28-day post-IVB/matching period and overall respiratory improvement at day 28 and at discharge. The duration of supplemental oxygen therapy following IVB/matching was documented.
A total of 5578 infants were included. Seventy-eight infants were enroled in the IVB group, and another 78 infants were matched as the control group. Both groups had downward trends in the MAP, FiO2, and RSS over the study period (all P < 0.001), but there were no between-group differences in these measures. The percentage of overall respiratory improvement was similar between the IVB and control groups, so was the duration of invasive and in-hospital oxygen ventilation. A lower percentage of oxygen dependence at discharge in the IVB group (P = 0.03) remained significant after adjusting for GA and BW.
This is a matched case study to evaluate respiratory outcomes in preterm infants following IVB for ROP. We found that the IVBs did not compromise respiratory outcomes in preterm infants during the 28-day post-IVB period and at discharge.
This single-centre study enroled preterm infants with a gestational age (GA) < 34 weeks or a birth weight (BW) < 1500 g with bilateral type 1 ROP who received a single IVB, and a treatment-free control group matched by GA, postmenstrual age, and respiratory status at the time of the IVB. The primary outcome was serial respiratory changes in mean airway pressure (MAP), fraction of inspired oxygen (FiO2), and respiratory severity score (RSS, MAP x FiO2) during the 28-day post-IVB/matching period and overall respiratory improvement at day 28 and at discharge. The duration of supplemental oxygen therapy following IVB/matching was documented.
A total of 5578 infants were included. Seventy-eight infants were enroled in the IVB group, and another 78 infants were matched as the control group. Both groups had downward trends in the MAP, FiO2, and RSS over the study period (all P < 0.001), but there were no between-group differences in these measures. The percentage of overall respiratory improvement was similar between the IVB and control groups, so was the duration of invasive and in-hospital oxygen ventilation. A lower percentage of oxygen dependence at discharge in the IVB group (P = 0.03) remained significant after adjusting for GA and BW.
This is a matched case study to evaluate respiratory outcomes in preterm infants following IVB for ROP. We found that the IVBs did not compromise respiratory outcomes in preterm infants during the 28-day post-IVB period and at discharge.
摘要：
目的：评估玻璃体内注射贝伐单抗（IVB）后早产儿视网膜病变（ROP）的呼吸结局。
方法：这项单中心研究纳入了胎龄（GA）<34周或出生体重（BW）<1500g且双侧1型ROP接受过一次IVB的早产儿，与GA匹配的无治疗对照组，月经后年龄，和IVB时的呼吸状态。主要结果是平均气道压（MAP）的连续呼吸变化，吸入氧气（FiO2）的分数，和呼吸严重程度评分(RSS，MAPxFiO2）在IVB/匹配期后28天以及第28天和出院时的总体呼吸改善。记录IVB/匹配后补充氧气治疗的持续时间。
结果：共纳入5578名婴儿。78名婴儿被纳入IVB组，另外78名婴儿作为对照组。两组的MAP都有下降趋势，研究期间的FiO2和RSS（均P<0.001），但这些指标没有组间差异.IVB组和对照组的总体呼吸改善百分比相似，侵入性和院内氧气通气的持续时间也是如此。调整GA和BW后，IVB组放电时的氧依赖性百分比较低（P=0.03）仍然显着。
结论：这是一项评估ROPIVB后早产儿呼吸结局的匹配案例研究。我们发现IVB在IVB后28天和出院时不会损害早产儿的呼吸结局。
方法：这项单中心研究纳入了胎龄（GA）<34周或出生体重（BW）<1500g且双侧1型ROP接受过一次IVB的早产儿，与GA匹配的无治疗对照组，月经后年龄，和IVB时的呼吸状态。主要结果是平均气道压（MAP）的连续呼吸变化，吸入氧气（FiO2）的分数，和呼吸严重程度评分(RSS，MAPxFiO2）在IVB/匹配期后28天以及第28天和出院时的总体呼吸改善。记录IVB/匹配后补充氧气治疗的持续时间。
结果：共纳入5578名婴儿。78名婴儿被纳入IVB组，另外78名婴儿作为对照组。两组的MAP都有下降趋势，研究期间的FiO2和RSS（均P<0.001），但这些指标没有组间差异.IVB组和对照组的总体呼吸改善百分比相似，侵入性和院内氧气通气的持续时间也是如此。调整GA和BW后，IVB组放电时的氧依赖性百分比较低（P=0.03）仍然显着。
结论：这是一项评估ROPIVB后早产儿呼吸结局的匹配案例研究。我们发现IVB在IVB后28天和出院时不会损害早产儿的呼吸结局。
